Skip to main content

MONITORIZACION DE LA MOVILIDAD DE ENFERMOS DE PARKINSON CON FINES TERAPEUTICOS - ENSAYO CLINICO (MOMOPA-EC)

DTS17/00195

•
Funding agency name Instituto de Salud Carlos III
Funding agency acronym ISCIII
Program Programa Estatal de Fomento de la Investigación Científica y Técnica de Excelencia
Subprogram Subprograma Estatal de Generación de Conocimiento
Call Proyectos de Desarrollo Tecnológico en Salud
Call year 2017
State Plan 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre CONSORCIO SANITARIO DEL GARRAF
Execution centre CONSORCIO SANITARIO DEL GARRAF

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Comparison of clinical measures of motor function with a Holter monitor in Parkinson's disease

  • Pérez-López, C.
  • Caballol, Nuria|||0000-0003-3363-3077
  • Buongiorno, M.
  • Ávila Rivera, Maria A.
  • Ariztegui, N.L.
  • López-Manzanares, L.
  • Hernández-Vara, Jorge|||0000-0002-9129-5224
  • Rusiñol, À.B.
  • Gironell, Alexandre|||0000-0003-2109-9030
  • Saúco, M.Á.
  • Gomez, E.F.
  • Pérez-Martínez, D.A.
  • Arroyo, S.E.
  • Martínez, S.M.
  • Mir, Pablo|||0000-0003-1656-302X
  • Salom Juan, J.M.
  • Martínez-Castrillo, J.C.
  • Rodríguez-Molinero, A.
Background: Parkinson's disease (PD) is a significant global health challenge, affecting millions worldwide. This sub-study aims to explore the potential of ambulatory monitoring devices in identifying disease severity and progression in patients. As part of the MOMOPA-EC clinical trial, 156 patients with moderate to severe PD underwent 435 assessments using clinical scales and ambulatory monitoring devices (Parkinson's Holter). This sub-study seeks to establish relations between parameters derived from Holter monitors and clinical severity measures to enhance personalized disease management strategies. Methods: In the MOMOPA-EC trial, 435 patient monitoring sessions were conducted, during which patients wore Parkinson's Holter monitors for a week before completing clinical assessments, including the Unified Parkinson's Disease Rating Scale (UPDRS), Parkinson's Disease Questionnaire (PDQ-39), and Freezing of Gait Questionnaire (FoG-Q). Results: The reports obtained during the monitoring of the patients were classified into three groups based on the greater or lesser gait fluidity (according to the measurements from the Parkinson's Holter). All clinical scales were significantly different in each of these groups, indicating that patients with lower stride fluidity had poorer outcomes across the different clinical scales. Conclusions: The findings of this study underscore the potential of Parkinson's Holters in providing objective data for personalized disease management in PD patients. Integrating such technologies into routine clinical practice could enhance patient care and treatment strategies by offering clinicians objective insights into both disease progression and therapeutic response.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Comparison of clinical measures of motor function with a Holter monitor in Parkinson's disease

  • Pérez-López, Carlos
  • Caballol, Nuria
  • Buongiorno, Mariateresa
  • Ávila Rivera, María Asunción
  • López-Ariztegui, Nuria
  • López-Manzanares, Lydia
  • Hernández-Vara, Jorge
  • Bayes Rusiñol, Àngels
  • Carreró, Alexandre Gironell
  • Álvarez-Sauco, María
  • Franquet Gómez, Elisabet
  • Pérez-Martínez, David A.
  • Escalante Arroyo, Sonia
  • Martí Martínez, Silvia
  • Mir, Pablo
  • Salom, José María
  • Martínez-Castrillo, Juan Carlos
  • Rodríguez-Molinero, Alejandro
[Trial registration] NCT04176302 Registered 18 November 2019, https://clinicaltrials.gov/show/NCT04176302., [Background] Parkinson’s disease (PD) is a significant global health challenge, affecting millions worldwide. This sub-study aims to explore the potential of ambulatory monitoring devices in identifying disease severity and progression in patients. As part of the MOMOPA-EC clinical trial, 156 patients with moderate to severe PD underwent 435 assessments using clinical scales and ambulatory monitoring devices (Parkinson’s Holter). This sub-study seeks to establish relations between parameters derived from Holter monitors and clinical severity measures to enhance personalized disease management strategies. Methods: In the MOMOPA-EC trial, 435 patient monitoring sessions were conducted, during which patients wore Parkinson’s Holter monitors for a week before completing clinical assessments, including the Unified Parkinson’s Disease Rating Scale (UPDRS), Parkinson’s Disease Questionnaire (PDQ-39), and Freezing of Gait Questionnaire (FoG-Q). Results: The reports obtained during the monitoring of the patients were classified into three groups based on the greater or lesser gait fluidity (according to the measurements from the Parkinson’s Holter). All clinical scales were significantly different in each of these groups, indicating that patients with lower stride fluidity had poorer outcomes across the different clinical scales. Conclusions: The findings of this study underscore the potential of Parkinson’s Holters in providing objective data for personalized disease management in PD patients. Integrating such technologies into routine clinical practice could enhance patient care and treatment strategies by offering clinicians objective insights into both disease progression and therapeutic response., This work is supported by the Instituto de Salud Carlos III [DTS17/00195], the “A way to make Europe” European Fund for Regional Development, and AbbVie S.L.U., Peer reviewed
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Multicentre, randomised, single-blind, parallel group trial to compare the effectiveness of a Holter for Parkinson's symptoms against other clinical monitoring methods, study protocol

  • Rodríguez-Molinero, Alejandro|||0000-0002-9678-2654
  • Hernández-Vara, Jorge|||0000-0002-9129-5224
  • Miñarro, Antonio
  • Pérez-López, Carlos|||0000-0001-7400-4360
  • Bayés, Àngels|||0000-0001-9542-804X
  • Martínez-Castrillo, Juan Carlos|||0000-0001-7744-6850
  • Pérez-Martínez, David Andrés|||0000-0001-5587-0415
In recent years, multiple studies have aimed to develop and validate portable technological devices capable of monitoring the motor complications of Parkinson's disease patients (Parkinson's Holter). The effectiveness of these monitoring devices for improving clinical control is not known. This is a single-blind, cluster-randomised controlled clinical trial. Neurologists from Spanish health centres will be randomly assigned to one of three study arms (1:1:1): (a) therapeutic adjustment using information from a Parkinson's Holter that will be worn by their patients for 7 days, (b) therapeutic adjustment using information from a diary of motor fluctuations that will be completed by their patients for 7 days and (c) therapeutic adjustment using clinical information collected during consultation. It is expected that 162 consecutive patients will be included over a period of 6 months. The primary outcome is the efficiency of the Parkinson's Holter compared with traditional clinical practice in terms of Off time reduction with respect to the baseline (recorded through a diary of motor fluctuations, which will be completed by all patients). As secondary outcomes, changes in variables related to other motor complications (dyskinesia and freezing of gait), quality of life, autonomy in activities of daily living, adherence to the monitoring system and number of doctor-patient contacts will be analysed. The noninferiority of the Parkinson's Holter against the diary of motor fluctuations in terms of Off time reduction will be studied as the exploratory objective. Ethics and dissemination approval for this study has been obtained from the Hospital Universitari de Bellvitge Ethics Committee. The results of this study will inform the practical utility of the objective information provided by a Parkinson's Holter and, therefore, the convenience of adopting this technology in clinical practice and in future clinical trials. We expect public dissemination of the results in 2022.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Comparison of the Results of a Parkinson's Holter Monitor With Patient Diaries, in Real Conditions of Use, A Sub-analysis of the MoMoPa-EC Clinical Trial

  • Pérez-López, Carlos|||0000-0001-7400-4360
  • Hernández-Vara, Jorge|||0000-0002-9129-5224
  • Caballol, Nuria|||0000-0003-3363-3077
  • Bayés, Àngels|||0000-0001-9542-804X
  • Buongiorno, María Teresa
  • Lopez-Ariztegui, Núria
  • Gironell, Alexandre|||0000-0003-2109-9030
  • López-Sánchez, José
  • Martínez-Castrillo, Juan Carlos|||0000-0001-7744-6850
  • Álvarez Sauco, María
  • López Manzanares, Lydia|||0000-0003-4615-4542
  • Escalante, Sonia|||0000-0001-8931-1400
  • Pérez-Martínez, David Andrés|||0000-0001-5587-0415
  • Rodríguez-Molinero, Alejandro|||0000-0002-9678-2654
Background: For specialists in charge of Parkinson's disease (PD), one of the most time-consuming tasks of the consultations is the assessment of symptoms and motor fluctuations. This task is complex and is usually based on the information provided by the patients themselves, which in most cases is complex and biased. In recent times, different tools have appeared on the market that allow automatic ambulatory monitoring. The MoMoPa-EC clinical trial (NCT04176302) investigates the effect of one of these tools-Sense4Care's STAT-ON-can have on routine clinical practice. In this sub-analysis the agreement between the Hauser diaries and the STAT-ON sensor is analyzed. Methods: Eighty four patients from MoMoPa-EC cohort were included in this sub-analysis. The intraclass correlation coefficient was calculated between the patient diary entries and the sensor data. Results: The intraclass correlation coefficient of both methods was 0.57 (95% CI: 0.3-0.73) for the OFF time (%), 0.48 (95% CI: 0.17-0.68) for the time in ON (%), and 0.65 (95% CI%: 0.44-0.78) for the time with dyskinesias (%). Furthermore, the Spearman correlations with the UPDRS scale have been analyzed for different parameters of the two methods. The maximum correlation found was -0.63 (p < 0.001) between Mean Fluidity (one of the variables offered by the STAT-dON) and factor 1 of the UPDRS. Conclusion: This sub-analysis shows a moderate concordance between the two tools, it is clearly appreciated that the correlation between the different UPDRS indices is better with the STAT-ON than with the Hauser diary. Trial Registration: https://clinicaltrials.gov/show/NCT04176302 (NCT04176302).